emperor-preserved-heart-failure-toplineresults

Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction  The EMPEROR-Preserved Phase III trial met its primary endpoint and demonstrated significant risk reduction with empagliflozin for the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction (HFpEF)HFpEF has been classified as “the single largest unmet need in cardiovascular medicine”1 based on prevalence, poor outcomes and the absence of clinically proven therapies to date2With approval, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of heart failure patients regardless of ejection fraction  
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news

Related Links:

AbstractReproducibility of clinical output is important when investigating therapeutic efficacy in pre-clinical animal studies. Due to its physiological relevance, a swine myocardial infarction (MI) model has been widely used to evaluate the effectiveness of stem cells or tissue-engineered constructs for ischemic heart diseases. Several methods are used to induce MI in the swine model. However, it is difficult, using these approaches, to obtain a similar level of functional outcomes from a group of animals due to interpersonal variation, leading to increased experimental cost. Hence, in order to minimize human intervention...
Source: European Journal of Applied Physiology - Category: Physiology Source Type: research
Empagliflozin reduced the risk of adverse cardiovascular and renal outcomes in heart failure patients regardless of baseline NT-proBNP levels, researchers say.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
Pulmonary artery pressure monitoring reduced hospitalizations of obese patients with heart failure, regardless of ejection fraction, in a post-hoc analysis of the CardioMEMS Post Approval Study.Reuters Health Information
Source: Medscape Radiology Headlines - Category: Radiology Tags: Cardiology News Source Type: news
Ann Biomed Eng. 2021 Sep 21. doi: 10.1007/s10439-021-02848-2. Online ahead of print.ABSTRACTA promising treatment for congestive heart failure is the implementation of a left ventricular assist device (LVAD) that works as a mechanical pump. Modern LVADs work with adjustable constant rotor speed and provide therefore continuous blood flow; however, recently undertaken efforts try to mimic pulsatile blood flow by oscillating the pump speed. This work proposes an algorithmic framework to construct and evaluate optimal pump speed policies with respect to generic objectives. We use a model that captures the atrioventricular pla...
Source: Annals of Biomedical Engineering - Category: Biomedical Engineering Authors: Source Type: research
Am J Physiol Cell Physiol. 2021 Sep 22. doi: 10.1152/ajpcell.00246.2021. Online ahead of print.ABSTRACTMitochondria have been recognized as key organelles in cardiac physiology and are potential targets for clinical interventions to improve cardiac function. Mitochondrial dysfunction has been accepted as a major contributor to the development of heart failure. The main function of mitochondria is to meet the high energy demands of the heart by oxidative metabolism. Ionic homeostasis in mitochondria directly regulates oxidative metabolism, and any disruption in ionic homeostasis causes mitochondrial dysfunction and eventual...
Source: Am J Physiol Cell Ph... - Category: Cytology Authors: Source Type: research
ConclusionsPatients with HFpEF in primary care are difficult to identify, and greater awareness of the condition, with clear diagnostic pathways and specialist support, are needed. Use of diagnostic algorithms and scores can provide systematic approaches to diagnosis but may be challenging to apply in older multi-morbid patients. Where diagnostic uncertainty remains, pragmatic decisions are needed regarding the value of additional testing versus management of presumptive HFpEF.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
ConclusionsA thorough baseline assessment of physical function and cognition is needed before beginning an exergame intervention. It is important to offer the possibility to exergame with others, to be able to adapt the intensity of physical activity.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
We report a case of rapidly progressed cardiac remodeling in a child with hypertrophic cardiomyopathy. Three and a half years after the diagnosis of hypertrophic cardiomyopathy, arrhythmia and heart failure due to aggravated septal hypertrophy and left ventricle apical aneurysm progressed, and a heart transplant was performed.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Case Anecdotes, Comments and Opinions Source Type: research
Heart failure is a global problem with high hospitalization and mortality rates. Inflammation and immune dysfunction are involved in this disease. Owing to their unique function, regulatory T cells (Tregs) have reacquired attention recently. They participate in immunoregulation and tissue repair in the pathophysiology of heart failure. Tregs are beneficial in heart by suppressing excessive inflammatory responses and promoting stable scar formation in the early stage of heart injury. However, in chronic heart failure, the phenotypes and functions of Tregs changed. They transformed into an antiangiogenic and profibrotic cell...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsIn SR patients with CAD and HF, the rates of MI and stroke associated with rivaroxaban combined with APT were lower than those associated with APT alone, and the two treatments had similar rates of all-cause death and major bleeding.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Empagliflozin | Heart | Heart Failure | Jardiance | Research